NIH Office of Technology Transfer (OTT) >> Abstract Search

Licensing & Royalties

Licensing Opportunities

Technology Abstracts

Interferon-Alpha SARS Treatment

Description of Invention:
The Public Health Service seeks a licensee to commercialize protein engineered human interferon alphas for treating and/or preventing a SARS-associated coronaviral infection in humans and other relevant mammalian species.

Inventors:
Kathryn C. Zoon (NCI)
Renqui Hu (NCI)
Joseph B. Bekisz (NCI)

Patent Status:
DHHS Reference No. E-278-2003/0 --
U.S. Provisional Application No. 60/567,083 filed 30 Apr 2004
PCT Application No. PCT/US2005/014800 filed 28 Apr 2005, which published as WO 2006/076014 on 20 Jul 2006

Related Technologies:
DHHS Reference No. E-165-2004 -- SARS Coronavirus MVA Vaccines and Therapy

DHHS Reference No. E-334-2003 -- Enhanced Sensitivity ELISA for SARS Diagnostic

DHHS Reference No. E-228-2003 -- Soluble SARS Coronavirus Spike Protein (S Protein)

Licensing Status:
This technology is no longer available for licensing.

Portfolios:
Infectious Diseases

Infectious Diseases -Therapeutics-Anti-Viral-Non-AIDS (only)
Infectious Diseases -Therapeutics
Infectious Diseases -Other

For Additional Information Please Contact:
Michael Shmilovich J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5019
Email: shmilovm@mail.nih.gov
Fax: (301) 402-0220

Web Ref: 943

Updated: 6/04